InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
4
T+90 hit rate
29%
T+90 mean return
-25.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Bonvini Ezio, Vice-Président Senior et Directeur Scientifique. Insider active across 1 company, notably Macrogenics INC. Aggregated, 18 reports have been published. Split: 0 buy · 4 sells. Total volume traded: €561k. Activity tracked since 24 June 2021. The latest transaction was filed on 15 February 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
16,665 shares0Common StockSEC:0001125345-25-000037:0
11,168 sharesCommon StockSEC:0001125345-25-000019:0
28,125 shares0Common StockSEC:0001125345-24-000046:0
16,670 shares0Common StockSEC:0001125345-24-000035:0
3,334 shares@ US$18.004.6% of flowCommon StockSEC:0001125345-24-000008:0
13,316 shares@ US$15.0015.2% of flowCommon StockSEC:0001125345-24-000004:0
13,316 shares@ US$12.0012.1% of flowCommon StockSEC:0001125345-24-000002:0
18,880 shares@ US$10.0814.2% of flowCommon StockSEC:0001125345-23-000131:0
9,375 shares0Common StockSEC:0001125345-23-000040:0
5,000 shares0Common StockSEC:0001125345-22-000051:0
2,540 shares@ US$16.000.013% mcap5.4% of flowCommon StockSEC:0001125345-21-000117:0
2,540 shares@ US$16.0010.9% of flowCommon StockSEC:0001125345-21-000117
21,855 shares@ US$16.000.11% mcap44.6% of flowCommon StockSEC:0001125345-21-000089:0
21,855 shares@ US$16.0024.1% of flowCommon StockSEC:0001125345-21-000089
5,000 sharesCommon StockSEC:0001125345-21-000084:0
5,000 sharesCommon StockSEC:0001125345-21-000084
4,421 sharesCommon StockSEC:0001140361-16-047431:0
8,895 sharesCommon StockSEC:0001140361-16-047431:1
18 of 18 declarations
About Bonvini Ezio
Ezio Bonvini is the Senior Vice President and Chief Scientific Officer at MacroGenics Inc. He is responsible for research and development of new products, playing a key role in the innovation and strategy of the company. His scientific expertise is essential for the growth of MacroGenics.
